Hansoh Pharmaceutical Group Company Limited (3692)

Name: Hansoh Pharmaceutical Group Company Limited (3692) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-30

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases.

Cifras clave

Capitalización bursátil: HK$214 billion
Ingresos (ejercicio cerrado en 2025-12-31): CNY 15.0B
Beneficio neto: CNY 5.6B
Margen bruto: 90.0%
Margen neto: 37.0%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Ingresos totales	CNY 15.0B	CNY 12.3B	CNY 10.1B	CNY 9.4B
Beneficio bruto	CNY 13.5B	CNY 11.2B	CNY 9.1B	CNY 8.5B
Ingresos operativos (EBIT)	CNY 5.5B	CNY 4.0B	CNY 2.8B	CNY 2.8B
Ingresos netos	CNY 5.6B	CNY 4.4B	CNY 3.3B	CNY 2.6B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 3692. /companies/us/3692

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.